샘플 요청 목록

 카트 문의
시장보고서
상품코드
1404004

세계 다낭성 난소 증후군 치료 시장 - 업계 분석, 규모, 점유율, 성장, 동향, 예측(2031년) : 약제 클래스별, 유통 채널별, 지역별

Polycystic Ovary Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
발행일: | 리서치사: Fairfield Market Research | 페이지 정보: 영문 306 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 다낭성 난소 증후군(PCOS) 치료 시장 규모는 2024년 말에 42억 달러에 달할 것으로 보입니다. 여성에 영향을 미치는 복잡한 내분비 질환인 PCOS는 난소낭종, 불임, 내분비 변동을 특징으로 합니다.

다낭성 난소 증후군(PCOS)은 세계 건강상의 주요 과제로 세계 수백만 명의 여성에게 영향을 미칩니다. 세계보건기구(WHO)에 따르면 세계에서 1억 1,600만 명 이상의 여성(3.4%)이 PCOS에 시달리고 있습니다. 미국에서만 PCOS는 생식 연령에 있는 여성의 6%에서 12%를 차지하며 여성 불임의 주요 원인이 되고 있습니다.

PCOS는 특정 연령대에 국한되지 않으며 폐경 후 여성에서도 지속될 수 있으며 대사의 변화와 심혈관 질환의 위험 상승으로 이어질 수 있습니다. 조기 진단과 치료는 증상을 완화 할뿐만 아니라 장기적인 영향을 예방하는 데에도 매우 중요합니다.

PCOS와 관련 위험에 대한 인식이 높아짐에 따라 진단과 치료에 대한 수요가 커지고 있습니다. PCOS 계발협회(PCOSAA)와 같은 계발 프로그램 및 이니셔티브는 진단률 향상에 기여하고 있습니다.

PCOS의 진단 건수 증가에 대응하기 위해, 제조업체는 의약품이나 영양 보조 식품의 유형를 늘리고 있습니다. 혁신적인 대안과 치료법의 개선은 채용률을 높일 것으로 예상됩니다.

FDA가 승인한 PCOS 치료제는 제한되어 있기 때문에 개인은 다른 목적으로 사용되는 적응 외 치료제를 사용해야 하는 상황입니다. PCOS 관련 증상에 대한 FDA 승인 치료제가 없다는 것은 시장 성장을 방해하고 있습니다.

저개발 경제권에서는 PCOS와 그 증상에 대한 인식이 현저히 낮습니다. 이는 치료에 대한 이해가 부족하거나 평온한 태도와 함께 시장 확대를 방해할 수 있습니다.

본 보고서에서는 세계의 다낭성 난소 증후군 치료 시장에 대해 조사했으며, 시장 개요와 함께 약물 클래스별, 유통 채널별, 지역별 동향 및 시장 진출기업의 경쟁 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 정의와 세분화
  • 시장 역학
  • 밸류체인 분석
  • Porter's Five Forces 분석
  • COVID-19의 영향 분석
  • 우크라이나와 러시아의 분쟁의 영향
  • 경제 개요
  • PESTLE 분석

제3장 세계의 다낭성 난소 증후군(PCOS) 치료 시장 전망(2018-2031년)

  • 세계의 다낭성 난소 증후군(PCOS) 치료 시장 전망, 약제 클래스별, 금액(10억 달러)(2018-2031년)
  • 세계의 다낭성 난소 증후군(PCOS) 치료 시장 전망, 유통 채널별, 금액(10억 달러)(2018-2031년)
  • 세계의 다낭성 난소 증후군(PCOS) 치료 시장 전망, 지역별, 금액(10억 달러)(2018-2031년)

제4장 북미의 다낭성 난소 증후군(PCOS) 치료 시장 전망(2018-2031년)

제5장 유럽의 다낭성 난소 증후군(PCOS) 치료 시장 전망(2018-2031년)

제6장 아시아태평양의 다낭성 난소증후군(PCOS) 치료시장 전망(2018-2031년)

제7장 라틴아메리카의 다낭성 난소 증후군(PCOS) 치료 시장 전망(2018-2031년)

제8장 중동 및 아프리카의 다낭성 난소 증후군(PCOS) 치료 시장 전망(2018-2031년)

제9장 경쟁 구도

  • 약품 클래스별과 유통 채널별 히트 맵
  • 기업의 시장 점유율 분석, 2023년
  • 경쟁력 대시보드
  • 기업 프로파일
    • Novartis AG
    • Sanofi
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc.(Merck group)
    • AstraZeneca plc.
    • Bayer AG
    • Abbott
    • Pfizer, Inc
    • Bristol-Myer Squibb Company
    • Ferring Pharmaceuticals, Inc.
    • Johnson and Johnson
    • Mylan NV
    • Allergan plc.
    • GlaxoSmithKline
    • Lupin Pharmaceuticals
    • AbbVie
    • Takeda
    • BIOCAD Global
    • Blairex Laboratories Inc

제10장 부록

JHS 24.01.18

The global polycystic ovary syndrome (PCOS) treatment market, valued at US$ 4.2 billion at the end of 2024, is forecasted to witness substantial growth, with an estimated valuation of US$ 6.11 billion by 2031. PCOS, a complex endocrine condition affecting women, is characterized by ovarian cysts, subfertility, and endocrine variations.

PCOS: A Global Health Concern

Polycystic ovarian syndrome (PCOS) poses a significant global health challenge, affecting millions of women worldwide. According to the World Health Organization (WHO), over 116 million women (3.4%) globally suffer from PCOS. In the United States alone, PCOS accounts for 6% to 12% of cases among women of reproductive age, making it a leading cause of female infertility.

PCOS is not limited to a specific age group, as it can persist even in postmenopausal women, leading to metabolic changes and an increased risk of cardiovascular disease. Early diagnosis and treatment are crucial not only to alleviate symptoms but also to prevent long-term consequences.

Opportunities for PCOS Drug Manufacturers:

Changing Lifestyles and Rising Awareness: With a growing awareness of PCOS and its associated risks, there is an increasing demand for diagnosis and treatment. Awareness programs and initiatives, such as PCOS Awareness Association (PCOSAA), are contributing to higher diagnosis rates.

Innovative Treatment Modalities: Manufacturers are offering an expanded range of drug formulations and dietary products to cater to the rising number of PCOS diagnoses. Innovative alternatives and improved treatment options are expected to boost adoption rates.

Challenges Faced by Market Players:

Unavailability of FDA-Approved Drugs: Limited FDA-approved drugs for PCOS treatment force individuals to use off-label drugs intended for different purposes. The absence of FDA-approved treatments for PCOS-related symptoms hinders market growth.

Lack of Awareness in Underdeveloped Economies: In underdeveloped economies, awareness regarding PCOS and its symptoms remains significantly low. This, coupled with a lack of understanding and a carefree attitude towards treatment, can hinder market expansion.

Country-Wise Insights:

Lucrative U.S. Market: The United States experiences rising healthcare costs and an increasing prevalence of PCOS-related disorders. Improved healthcare infrastructure, rising disposable income, and government-led awareness initiatives contribute to market growth.

Growing Indian Market: India has witnessed a surge in PCOS diagnoses, with approximately 22.5% of women affected. Increased awareness, changing lifestyles, and dietary habits are driving the demand for PCOS treatment in the country.

Competitive Landscape:

Leading manufacturers and pharmaceutical companies are focusing on developing innovative products to strengthen their global product pipelines. Collaborations and consolidation activities with other firms are being pursued to expedite research, development, and distribution.

Key Companies Profiled:

  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • Merck & Co., Inc. (Merck group)
  • AstraZeneca plc.
  • Bayer AG
  • Abbott
  • Pfizer, Inc
  • Bristol-Myer Squibb Company
  • Ferring Pharmaceuticals, Inc.
  • Johnson and Johnson
  • Mylan N.V.
  • Allergan plc.
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • AbbVie
  • Takeda
  • BIOCAD Global
  • Blairex Laboratories Inc
  • Agile Therapeutics

Key Segments of PCOS Treatment Industry Research

By Drug Class:

  • Oral Contraceptives
  • Insulin Sensitizing Agents
  • Antidepressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs
  • Diuretics

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores/OTC
  • e-Commerce
  • Clinics

By Region:

  • North America
  • Latin America
  • Europe Polycystic
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Oral Contraceptives
      • 3.1.1.2. Insulin Sensitizing Agents
      • 3.1.1.3. Antidepressants
      • 3.1.1.4. Ornithine Decarboxylase Inhibitors
      • 3.1.1.5. Aromatase Inhibitors & SERMs
      • 3.1.1.6. Diuretics
  • 3.2. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Drug Stores/OTC
      • 3.2.1.3. e-Commerce
      • 3.2.1.4. Clinics
  • 3.3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Oral Contraceptives
      • 4.1.1.2. Insulin Sensitizing Agents
      • 4.1.1.3. Antidepressants
      • 4.1.1.4. Ornithine Decarboxylase Inhibitors
      • 4.1.1.5. Aromatase Inhibitors & SERMs
      • 4.1.1.6. Diuretics
  • 4.2. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Drug Stores/OTC
      • 4.2.1.3. e-Commerce
      • 4.2.1.4. Clinics
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Oral Contraceptives
      • 5.1.1.2. Insulin Sensitizing Agents
      • 5.1.1.3. Antidepressants
      • 5.1.1.4. Ornithine Decarboxylase Inhibitors
      • 5.1.1.5. Aromatase Inhibitors & SERMs
      • 5.1.1.6. Diuretics
  • 5.2. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Drug Stores/OTC
      • 5.2.1.3. e-Commerce
      • 5.2.1.4. Clinics
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Oral Contraceptives
      • 6.1.1.2. Insulin Sensitizing Agents
      • 6.1.1.3. Antidepressants
      • 6.1.1.4. Ornithine Decarboxylase Inhibitors
      • 6.1.1.5. Aromatase Inhibitors & SERMs
      • 6.1.1.6. Diuretics
  • 6.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Drug Stores/OTC
      • 6.2.1.3. e-Commerce
      • 6.2.1.4. Clinics
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Oral Contraceptives
      • 7.1.1.2. Insulin Sensitizing Agents
      • 7.1.1.3. Antidepressants
      • 7.1.1.4. Ornithine Decarboxylase Inhibitors
      • 7.1.1.5. Aromatase Inhibitors & SERMs
      • 7.1.1.6. Diuretics
  • 7.2. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Drug Stores/OTC
      • 7.2.1.3. e-Commerce
      • 7.2.1.4. Clinics
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Oral Contraceptives
      • 8.1.1.2. Insulin Sensitizing Agents
      • 8.1.1.3. Antidepressants
      • 8.1.1.4. Ornithine Decarboxylase Inhibitors
      • 8.1.1.5. Aromatase Inhibitors & SERMs
      • 8.1.1.6. Diuretics
  • 8.2. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Drug Stores/OTC
      • 8.2.1.3. e-Commerce
      • 8.2.1.4. Clinics
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drug Class vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novartis AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Sanofi
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Teva Pharmaceutical Industries Limited
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc. (Merck group)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. AstraZeneca plc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Bayer AG
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Abbott
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Pfizer, Inc
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Bristol-Myer Squibb Company
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Ferring Pharmaceuticals, Inc.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Therapy Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Johnson and Johnson
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Therapy Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Mylan N.V.
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Therapy Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Allergan plc.
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Therapy Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. GlaxoSmithKline
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Therapy Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Lupin Pharmaceuticals
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Therapy Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development
    • 9.4.16. AbbVie
      • 9.4.16.1. Company Overview
      • 9.4.16.2. Therapy Portfolio
      • 9.4.16.3. Financial Overview
      • 9.4.16.4. Business Strategies and Development
    • 9.4.17. Takeda
      • 9.4.17.1. Company Overview
      • 9.4.17.2. Therapy Portfolio
      • 9.4.17.3. Financial Overview
      • 9.4.17.4. Business Strategies and Development
    • 9.4.18. BIOCAD Global
      • 9.4.18.1. Company Overview
      • 9.4.18.2. Therapy Portfolio
      • 9.4.18.3. Financial Overview
      • 9.4.18.4. Business Strategies and Development
    • 9.4.19. Blairex Laboratories Inc
      • 9.4.19.1. Company Overview
      • 9.4.19.2. Therapy Portfolio
      • 9.4.19.3. Financial Overview
      • 9.4.19.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제